Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer

Research on the Transformation of Postoperative Adjuvant Therapy of Tumor Antigen-sensitized DC Vaccine Applied to Esophagus Cancer

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.

Inclusion Criteria:

• Pathologically confirmed diagnosis of esophageal squamous cell carcinoma；
• Immunotherapy for preoperative；
• Karnofsky performance status 0-1;
• The postoperative pathological stage is (y) Pt + and / or N + M0 according to AJCC 8th
• Function of the main organs is normal;
• Edition Patient's written informed consent

Exclusion Criteria:

• Tumor emergencies;
• Abnormal coagulation function;
• Contagious diseases, such as HIV, HBV, HCV infection;
• Mental disorders;
• Concomitant tumors;
• Immunological co-morbidities